Document is current
Any future updates will be listed below
-
Authors
Catania, Marcella
Battipaglia, Claudia
Perego, Alberto
Salvi, Erika
Maderna, Emanuela
Cazzaniga, Federico Angelo
Rossini, Paolo M.
Marra, Camillo
Vanacore, Nicola
Redolfi, Alberto
Perani, Daniela
Spadin, Patrizia
Cotelli, Maria
Cappa, Stefano
Caraglia, Naike
Tiraboschi, Pietro
Tagliavini, Fabrizio
Di Fede, Giuseppe
-
Funding
Funding for this research was provided by:
Italian Ministry of Health - Ricerca Corrente
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
Agenzia Italiana del Farmaco, Ministero della Salute (Progetto Strategico AIFA - Interceptor)
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 12 January 2025
First Online: 21 January 2025
Declarations
:
: The study was conducted in compliance with the Declaration of Helsinki for the protection of human participants and was approved by the Ethics Committee of Fondazione Policlinico Universitario Agostino Gemelli (approval code 2251). Additionally, approval was obtained from all local ethics committees of the participating clinical centres. Written informed consent was obtained from participants.
: N/A.
: A.P. is an employee of Fujirebio.
